Seeking Alpha

The FDA LLY) lung cancer treatment Alimta, now saying that patients may receive the drug as a...

The FDA has approved a new use for Eli Lilly's (LLY) lung cancer treatment Alimta, now saying that patients may receive the drug as a maintenance therapy following first-line treatment. The FDA cites Phase III data, the first of its kind, that demonstrates better overall survival advantages with continued maintenance. Shares +1% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs